202 related articles for article (PubMed ID: 32097841)
41. JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.
Chi F; Chen L; Wang C; Li L; Sun X; Xu Y; Ma T; Liu K; Ma X; Shu X
Bioorg Chem; 2020 Jan; 95():103542. PubMed ID: 31918398
[TBL] [Abstract][Full Text] [Related]
42. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.
Oh K; Joo KM; Jung YS; Lee J; Kang H; Lee HY; Lee DS
J Immunol Methods; 2010 Mar; 354(1-2):45-52. PubMed ID: 20138049
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
[TBL] [Abstract][Full Text] [Related]
44. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
45. Generation of a chemical genetic model for JAK3.
Remenyi J; Naik RJ; Wang J; Razsolkov M; Verano A; Cai Q; Tan L; Toth R; Raggett S; Baillie C; Traynor R; Hastie CJ; Gray NS; Arthur JSC
Sci Rep; 2021 May; 11(1):10093. PubMed ID: 33980892
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
47. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
de Vicente J; Lemoine R; Bartlett M; Hermann JC; Hekmat-Nejad M; Henningsen R; Jin S; Kuglstatter A; Li H; Lovey AJ; Menke J; Niu L; Patel V; Petersen A; Setti L; Shao A; Tivitmahaisoon P; Vu MD; Soth M
Bioorg Med Chem Lett; 2014 Nov; 24(21):4969-75. PubMed ID: 25262541
[TBL] [Abstract][Full Text] [Related]
48. Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.
Lynch SM; DeVicente J; Hermann JC; Jaime-Figueroa S; Jin S; Kuglstatter A; Li H; Lovey A; Menke J; Niu L; Patel V; Roy D; Soth M; Steiner S; Tivitmahaisoon P; Vu MD; Yee C
Bioorg Med Chem Lett; 2013 May; 23(9):2793-800. PubMed ID: 23540648
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
50. Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
Clark MP; George KM; Bookland RG; Chen J; Laughlin SK; Thakur KD; Lee W; Davis JR; Cabrera EJ; Brugel TA; VanRens JC; Laufersweiler MJ; Maier JA; Sabat MP; Golebiowski A; Easwaran V; Webster ME; De B; Zhang G
Bioorg Med Chem Lett; 2007 Mar; 17(5):1250-3. PubMed ID: 17189692
[TBL] [Abstract][Full Text] [Related]
51. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
Farmer LJ; Ledeboer MW; Hoock T; Arnost MJ; Bethiel RS; Bennani YL; Black JJ; Brummel CL; Chakilam A; Dorsch WA; Fan B; Cochran JE; Halas S; Harrington EM; Hogan JK; Howe D; Huang H; Jacobs DH; Laitinen LM; Liao S; Mahajan S; Marone V; Martinez-Botella G; McCarthy P; Messersmith D; Namchuk M; Oh L; Penney MS; Pierce AC; Raybuck SA; Rugg A; Salituro FG; Saxena K; Shannon D; Shlyakter D; Swenson L; Tian SK; Town C; Wang J; Wang T; Wannamaker MW; Winquist RJ; Zuccola HJ
J Med Chem; 2015 Sep; 58(18):7195-216. PubMed ID: 26230873
[TBL] [Abstract][Full Text] [Related]
52. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
[TBL] [Abstract][Full Text] [Related]
53. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.
McDonnell ME; Bian H; Wrobel J; Smith GR; Liang S; Ma H; Reitz AB
Bioorg Med Chem Lett; 2014 Feb; 24(4):1116-21. PubMed ID: 24461299
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
[TBL] [Abstract][Full Text] [Related]
55. Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.
Lin TH; Hegen M; Quadros E; Nickerson-Nutter CL; Appell KC; Cole AG; Shao Y; Tam S; Ohlmeyer M; Wang B; Goodwin DG; Kimble EF; Quintero J; Gao M; Symanowicz P; Wrocklage C; Lussier J; Schelling SH; Hewet AG; Xuan D; Krykbaev R; Togias J; Xu X; Harrison R; Mansour T; Collins M; Clark JD; Webb ML; Seidl KJ
Arthritis Rheum; 2010 Aug; 62(8):2283-93. PubMed ID: 20506481
[TBL] [Abstract][Full Text] [Related]
56. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
[TBL] [Abstract][Full Text] [Related]
57. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
58. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
60. PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Xu H; Jesson MI; Seneviratne UI; Lin TH; Sharif MN; Xue L; Nguyen C; Everley RA; Trujillo JI; Johnson DS; Point GR; Thorarensen A; Kilty I; Telliez JB
ACS Chem Biol; 2019 Jun; 14(6):1235-1242. PubMed ID: 31082193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
